Medical technology company launches on StartEngine with a solution for drug-addicted patients during the opioid epidemic


BOCA RATON, Florida., April 5, 2022 /PRNewswire/ — Speranza Therapeutics is pleased to announce its engagement with StartEngine to attract new investors to support its companythe growth. StartEngine Crowdfunding, Inc. is the largest crowdfunding platform in the United States. On StartEngine, ordinary people can invest and buy shares in startups and start-ups.

The worsening opioid epidemic has ignited Speranza’s passion to reach more providers and patients. Opioid use disorder (OUD) and addiction associated with the stress of navigating a pandemic present a complex, multi-faceted treatment problem that can result in death from overdose. Recently, the CDC reported that there have been more than 105,000 overdose deaths in the past 12 months – a staggering increase from 78,000 deaths in 2020. Nearly two-thirds of all overdoses involved fentanyl and other synthetic opioids.

“Now more than ever, we need to provide clinical solutions to maintain treatment for patients with OUD,” says Sal J. Rafanelli, RPh, President and CEO. “The fear of withdrawal can be overwhelming and often prevents patients from starting or continuing their treatment. We wanted to join StartEngine to give everyone the opportunity to join us in our mission to provide clinically effective therapies and treatment technologies to patients in need.

Speranza Therapeutics offers a new treatment to help kick-start recovery by relieving opioid withdrawal symptoms during detox. His ST Genesis device may play a pivotal role in reducing the withdrawal symptoms that many opioid-dependent patients may face when trying to quit or cut down.

FDA-cleared device supports reduction of opioid withdrawal symptoms – nausea, muscle cramps, anxiety, sweating, tremors, joint pain, increased heart rate and insomnia – by targeting areas of the brain responsible for pain and anxiety. The non-invasive, drug-free device is easily applied to the ear by any provider and delivers treatment for 5 days, helping the patient during the most critical time as it reduces opioid use.

Speranza Therapeutics is in a period of explosive growth. Over the past 9 months, the company’s valuation has increased by 256%, paving the way for rapid expansion to reach more patients. For more information visit Speranzathe investor page at

About Speranza Therapeutics
Founded in 2019, Speranza Therapeutics is more than a company that delivers a drug or device to a patient or physician. We provide solutions within a medical protocol that help produce positive outcomes for struggling patients.

Media Contact:
Todd Krasinsky
[email protected]

SOURCE Speranza Therapeutics

Source link


Comments are closed.